Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03001128 · ClinicalTrials.gov registry record
Biomarkers to Predict Time to Plasma HIV RNA Rebound
A clinical trial of HIV-1-infection, sponsored by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections.
- Completed
- Registry status
- 61
- Enrollment target
- 18
- Study locations
NCT03001128: Completed study of HIV-1-infection, sponsored by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections.
NCT03001128 is a study of HIV-1-infection that has completed, run by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections. The registered enrollment target is 61 participants, below the 351-participant average among 71 other HIV-1-infection trials with a reported enrollment target (83% lower). The trial reports 18 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03001128, a study of HIV-1-infection, has completed, sponsored by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections.
- COMPLETED
- Registry status
- 61 participants
- Enrollment target
- 18
- Study locations
Study Summary
The purpose of this study is to collect information about what happens when people pause, or temporarily stop taking, ART, and to collect blood samples from these people at frequent intervals. We will also study the safety of pausing ART under close observation.
Primary Outcome
Time from ART discontinuation (start of MAP) to HIV RNA rebound to ≥ 1,000 copies/mL
Conditions Studied
Interventions
- DRUG Antiretroviral treatment pause
Study Locations (18)
California
- 601 University of California, Los Angeles CARE Center CRS - Los Angeles
- 701 University of California, San Diego AntiViral Research Center CRS - San Diego
- 801 University of California, San Francisco HIV/AIDS CRS - San Francisco
Illinois
- 2701 Northwestern University CRS - Chicago
- Rush Univ. Med. Ctr. ACTG CRS (2702) - Chicago
Massachusetts
- 101 Massachusetts General Hospital (MGH) CRS - Boston
- 107 Brigham and Women's Hosp. ACTG CRS - Boston
North Carolina
- 3201 Chapel Hill CRS - Chapel Hill
- 3203 Greensboro CRS - Greensboro
Colorado
- University of Colorado Hospital CRS (6101) - Aurora
District of Columbia
- Whitman Walker Health CRS (31791) - Washington D.C.
Missouri
- Washington U CRS (2101) - St Louis
New York
- University of Rochester Adult HIV Therapeutic Strategies Network CRS (31787) - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2017-02-23 |
| Est. Completion | 2021-01-29 |
What the finished NCT03001128 record still lists
NCT03001128 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 61 participants, a relatively small participant target, below the 351-participant average among 71 other HIV-1-infection trials with a reported enrollment target (83% lower).
The record links to 1 condition, with HIV-1-infection appearing as the primary indexed condition, and to 1 intervention - of which Antiretroviral treatment pause is the first listed.
NCT03001128 lists 18 locations in 13 states (California, Illinois, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT03001128 about?
NCT03001128 is a clinical study titled "Biomarkers to Predict Time to Plasma HIV RNA Rebound". The purpose of this study is to collect information about what happens when people pause, or temporarily stop taking, ART, and to collect blood samples from these people at frequent intervals. We will also study the safety of pausing ART under close observation.
What is the current status of trial NCT03001128?
This trial is currently completed. The enrollment target is 61 participants. The study started on 2017-02-23. Estimated completion is 2021-01-29.
What conditions does trial NCT03001128 study?
This clinical trial studies the following conditions: HIV-1-infection.
What interventions are being tested in trial NCT03001128?
The interventions under investigation include: Antiretroviral treatment pause (DRUG).
Who is sponsoring clinical trial NCT03001128?
This trial is sponsored by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, which has 45 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03001128 being conducted?
This trial has 18 study locations across California, Colorado, District of Columbia, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV-1-infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03001128's enrollment target sits among peer trials
61 43rd of 71 higher than 28 of 71 other HIV-1-infection trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV-1-infection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Improving Coronary Vascular Health in Women
RECRUITING · Phase 2
-
Study of GS-3242 in Participants With HIV-1; Substudy-05
RECRUITING · Phase 1
-
Acceptance and Commitment Therapy for HIV+ Hazardous Drinkers
RECRUITING · NA
-
Understanding Practices of Lactation and Infant Feeding Together With Women With HIV in the United States
RECRUITING
-
Ending the Epidemic Interventions in the Dental Setting - UH3
RECRUITING · NA
-
Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04115306 · 61 participants · Phase 1
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
- NCT05070845 · 61 participants · Phase 2
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
- NCT05187832 · 61 participants · Phase 1
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
- NCT05269316 · 61 participants · Phase 1
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI